The continuing role of chemotherapy in the management of advanced urothelial cancer.
- Published in:
- Therapeutic Advances in Urology, 2018, v. 10, n. 12, p. 455, doi. 10.1177/1756287218814100
- By:
- Publication type:
- Article
Works matching IS 17562872 AND DT 2018 AND VI 10 AND IP 12
Results: 12
1
2
Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials.
- Published in:
- Therapeutic Advances in Urology, 2018, v. 10, n. 12, p. 445, doi. 10.1177/1756287218811450
- By:
- Publication type:
- Article
3
Risk stratification by means of biological age-related factors better predicts cancer-specific survival than chronological age in patients with upper tract urothelial carcinoma: a multi-institutional database study.
- Published in:
- Therapeutic Advances in Urology, 2018, v. 10, n. 12, p. 403, doi. 10.1177/1756287218811050
- By:
- Publication type:
- Article
4
New oral anti-coagulation drugs and prostate biopsy: a call for guidelines.
- Published in:
- Therapeutic Advances in Urology, 2018, v. 10, n. 12, p. 437, doi. 10.1177/1756287218811037
- By:
- Publication type:
- Article
5
The impact of patient-related nonmodifiable factors on perioperative outcomes following radical cystectomy with enhanced recovery protocol.
- Published in:
- Therapeutic Advances in Urology, 2018, v. 10, n. 12, p. 393, doi. 10.1177/1756287218811019
- By:
- Publication type:
- Article
6
Best practice in the management of benign prostatic hyperplasia in the patients requiring anticoagulation.
- Published in:
- Therapeutic Advances in Urology, 2018, v. 10, n. 12, p. 431, doi. 10.1177/1756287218807591
- By:
- Publication type:
- Article
7
Comparison of overall survival and unplanned hospital readmissions between partial and radical nephrectomy for cT1a and cT1b renal masses.
- Published in:
- Therapeutic Advances in Urology, 2018, v. 10, n. 12, p. 383, doi. 10.1177/1756287218810313
- By:
- Publication type:
- Article
8
Once-daily 5 mg tadalafil oral treatment for patients with chronic prostatitis/chronic pelvic pain syndrome.
- Published in:
- Therapeutic Advances in Urology, 2018, v. 10, n. 12, p. 377, doi. 10.1177/1756287218808677
- By:
- Publication type:
- Article
9
Criteria for indication and treatment modification in a cohort of patients with prostate cancer treated with hormone therapy.
- Published in:
- Therapeutic Advances in Urology, 2018, v. 10, n. 12, p. 365, doi. 10.1177/1756287218808496
- By:
- Publication type:
- Article
10
Advances in the management of upper tract urothelial carcinoma: improved endoscopic management through better diagnostics.
- Published in:
- Therapeutic Advances in Urology, 2018, v. 10, n. 12, p. 421, doi. 10.1177/1756287218805334
- By:
- Publication type:
- Article
11
Mirabegron, alone and in combination, in the treatment of overactive bladder: real-world evidence and experience.
- Published in:
- Therapeutic Advances in Urology, 2018, v. 10, n. 12, p. 411, doi. 10.1177/1756287218801282
- By:
- Publication type:
- Article
12
Changes in prostate apparent diffusion coefficient values during radiotherapy after neoadjuvant hormones.
- Published in:
- Therapeutic Advances in Urology, 2018, v. 10, n. 12, p. 359, doi. 10.1177/1756287218798748
- By:
- Publication type:
- Article